Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma

Publication Date: March 1, 2021

Key Points

Key Points

  • Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
  • NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.

Treatment

...eatment

...py: For Patients with Stage II to IVA Nasop...

...tion 1.1For all nasopharyngeal carcinoma (...

...ation 1.2For all NPC patients, both sequent...

...on 1.3For all NPC patients, a presc...

...on 1.4For all NPC patients, gross tumor volume...

...1.5For NPC patients who have under...

....6The delineation of elective nodal vol...


...motherapy Sequen...

....1For T2N0 (AJCC 8th) NPC patients, chem...

...tion 2.2For T1-2N1 (AJCC 8th) NPC pat...

...ommendation 2.3For Stage III–IVA (ex...

...mendation 2.4For Stage III–IVA (except T3N0) (AJ...

...ion 2.5For T3N0 (AJCC 8th) NPC patients, con...


...ent Chemotherapy...

...tion 3.1For all NPC patients without...

...n 3.2For all NPC patients without contraindicat...

....3For NPC patients with a contraindication...

...ion 3.4For NPC patients with a contraindicatio...


...nduction Chemoth...

...ommendation 4.1For all NPC patients r...

....2For NPC patients receiving induction chemoth...

...on 4.3For NPC patients receiving induction c...


...uvant Chemothe...

....1For all NPC patients receiving adjuvant...

...endation 5.2For all NPC patients receiving...

...mendation 5.3For all NPC patients receiving adju...


...Stage II to IVA Nasopharyngeal Carcinoma...